| 產品編號 |
bs-46010P |
| 英文名稱 |
Recombinant SARS-Cov-2 Spike S1 protein (D614G), His & Avi (HEK293)
|
| 中文名稱 |
重組SARS冠狀病毒2 Spike突變蛋白S1 (D614G)(His-Avi) |
| 別 名 |
SARS-CoV-2 spike protein; 2019-nCOV Spike protein; Spike glycoprotein; Spike protein S1; Surface glycoprotein; Spike protein RBD; SPIKE_SARS2; 2019-nCOV Spike S1(D614G), Recombinant (His-Avi Tag); Recombinant SARS-Cov-2 Spike S1 protein (D614G), His & Avi 突變型新冠蛋白; 新冠病毒S蛋白突變體（D614G）; 重組新冠病毒 Spike突變蛋白RBD(D614G); 新型冠狀病毒Spike突變體蛋白; |
| 理論分子量 |
77.9 kDa |
| 檢測分子量 |
110-130 |
| 性 狀 |
Lyophilized or Liquid |
| 濃 度 |
＞0.5 mg/ml |
| 物 種 |
SARS-Cov-2 |
| 序 列 |
14-683/1273 |
| 純 度 |
>95% as determined by SDS-PAGE |
| 純化方法 |
AC |
| 內毒素 |
Not analyzed |
| 表達系統 |
HEK293 cell |
| 活性 |
Yes |
| 標簽 |
His & Avi |
| 緩 沖 液 |
Lyophilized from 0.22um filtered solution in PBS (pH7.4). Normally 5% trehalose is added as protectant before lyophilization. |
| 保存條件 |
Stored at -70℃ or -20℃. Avoid repeated freeze/thaw cycles. |
| 注意事項 |
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| 產品介紹 |
The SARS-CoV-2 spike (S) protein is the target of vaccine design efforts to end the COVID-19 pandemic. Despite a low mutation rate, isolates with the D614G substitution in the S protein appeared early during the pandemic, and are now the dominant form worldwide. Here, we analyze the D614G mutation in the context of a soluble S ectodomain construct.
|
|
|
